EMPLICITI®

(Elotuzumab)

Documentation

Patented
Approved 2015
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: ADCC
Target: CD319(SLAMF7)
Indication Category: Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA